Which famous company does ruxolitinib/ruxolitinib cream come from? This article will help you understand!

Ruxolitinib/ruxolitinib cream (ruxolitinib) is developed and produced by Incyte Corporation, a well-known American pharmaceutical company. Incyte was founded in 1991 and is headquartered in Delaware, USA. It is a biopharmaceutical company focusing on the research and development of immunology and oncology drugs. The company is not only committed to developing innovative treatments, but also bringing to market a variety of breakthrough drugs globally. As an important drug of Incyte, ruxolitinib cream is mainly used to treat skin diseases such as atopic dermatitis (AD) and vitiligo. Its launch marks a major advancement in the field of immunological treatment.

Ruxolitinib cream, as a selective Janus kinase (JAK) inhibitor, can effectively reduce skin inflammation, relieve patients' symptoms, and improve their quality of life. With its unique mechanism of action, the application of ruxolitinib cream in dermatology has gradually gained wide recognition, and it has also provided a new treatment option for many patients with chronic skin diseases.

When Incyte promotes ruxolitinib cream globally, it has obtained approval from regulatory agencies in many countries and is widely used in European and American markets. The company continues to promote the development and application of innovative drugs by cooperating with major pharmaceutical manufacturers around the world, and ruxolitinib cream has become one of its important breakthroughs in recent years. Ruxolitinib cream is a significant treatment advance for patients who need treatment for skin conditions such as atopic dermatitis.

Ruxolitinib cream, as aJAK inhibitor, has significant anti-inflammatory effects and provides a new direction for the treatment of atopic dermatitis and vitiligo. With topical application, patients can see significant symptom improvement in a short period of time with relatively few side effects.

Reference: https://www.opzelura.com/